Immunohistochemistry (IHC) analysis demonstrated hormone receptor positivity, with the tumor being Estrogen Receptor-positive (ER+) and Progesterone Receptor-positive (PR+) but Human Epidermal Growth Factor Receptor 2-negative (HER2-). Here, ERBB2 is linked to neoplasm.